New protocol: Venetoclax 600 daily + Cytarabine 20 mg subQ d1-10 (28d) for Acute Myeloid Leukemia

New protocol: Venetoclax 600 daily + Cytarabine 20 mg subQ d1-10 (28d) for Acute Myeloid Leukemia

Placebo controlled phase 3 trial
Venetoclax + subQ cytrabine (n=143) vs. placebo + subQ cytarabine (n=68)
CR: 48% vs. 15%
Median OS: 8.4 mo vs. 4.1 mo (HR 0.70 [0.50 – 0.99])
Grade >=3 adverse events: Neutropenia (49% vs. 18%), febrile neutropenia (32% vs. 29%). Tumor lysis in 5.6% in venetoclax arm

Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 7511-7511.
Wei HA, et al. A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.
https://doi.org/10.1200/JCO.2020.38.15_suppl.7511

Reviewed by Ulas Darda Bayraktar, MD on Oct 16, 2020

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More